Physician's Weekly

JUNE 18, 2025

Other Persistent Barriers & Potential Solutions In another article not presented at the meeting, Stephanie W. GLP-1 agonists are effective treatments for weight management, and although regulatory bodies and medical providers are on the right path, we have a long way to go,” the researchers concluded.

Healthcare Professional 52

Healthcare Professional Insurance Manufacturing Healthcare 52

FDA Law

JANUARY 16, 2025

While HPM prides itself on being the largest dedicated FDA law firm in the United States, it is small by design, so it is the quality of each of these individuals and what they contribute to the firm that is most exciting, said HPM managing Director J.P. She already has broad-based exposure to a variety of FDA regulated products.

IT 59

IT Manufacturing Management Individual 59

GeriPal

MARCH 2, 2023

I could go on and on, but listen to the podcast instead and for a deeper dive, take a look at the following articles and studies: Gabapentin in the Perioperative setting: Prolonged use of newly prescribed gabapentin after surgery. 2022 Perioperative Gabapentin Use in Older AdultsRevisiting Multimodal Pain Management JAMA IM.

Patient-Centered 96

Patient-Centered IT Healthcare Medical 96

GeriPal

MAY 8, 2025

And it kind of made its way into medicine probably around, I’m going to say the 50s after there was a fairly interesting Time Life article that was published. And when that article went to print, it just went ballistic. Gordon Alwasa. Am I saying that right? I always get. So I can say anything I want. So 5ht2 was.

Illness 106

Illness IT Patient-Centered Patients 106

GeriPal

DECEMBER 7, 2023

was supported by the fossil fuel industry , because it shifted responsibility for change from industry to individuals. So it’s hard to know about individual practice when I think of geriatrics or geriatric nursing because a lot of the solutions are really broad scale public health initiatives are needed, don’t you think?

Healthcare 128

Healthcare IT Education Community 128

FDA Law

SEPTEMBER 13, 2021

A final OIG rule to change the structure of manufacturer rebates to Medicare Part D and Medicaid Managed Care plans and their PBMs is enmeshed in litigation and is likely to be at least postponed until 2026 (see our post ), and perhaps prevented from implementation altogether, by Congressional mandate.

Manufacturing 98

Manufacturing Supply Chain Patient-Centered Utilities 98